表紙
市場調查報告書
商品編碼
1072658

癌症免疫診斷的全球市場預測:執行/顧問建議和自定義預測分析/分析(2022-2026)

Market Forecasts for Immuno-Oncology Diagnostics. Including Executive/Consultant Guides and Customized Forecasting/Analysis. 2022 to 2026

出版日期: | 出版商: Howe Sound Research | 英文 449 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告對癌症免疫診斷技術和市場進行了分析,概述了技術和主要應用領域、行業基本結構、主要市場促進/制約因素以及主要公司的最新情況、概況和支柱。我們將為您提供包括產品、未來市場規模趨勢以及按地區、應用、技術和客戶劃分的詳細趨勢等信息。

目錄

第一章市場指南

第二章市場的介紹和定義

  • 什麼是癌症免疫診斷?
  • 癌症免疫:即將到來的治療
  • 市場定義
  • 調查方法
  • 展望:醫療保健和 IVD(體外診斷)行業

第 3 章免疫療法:免疫技術指南

  • 免疫系統
    • 先天免疫系統
    • 適應性免疫系統
    • 癌症免疫:免疫監測系統
  • 癌症免疫診斷
    • 檢查點檢測
    • 細胞因子檢測
    • 基因組種系
    • 基因組腫瘤
    • 腫瘤微環境
    • 其他

第四章行業概況

  • 在充滿活力的市場中進入公司
    • 教育研究機構
    • 診斷測試開發人員
    • 基因組儀器供應商
    • 細胞分離/顯示設備供應商
    • 醫藥/試劑供應商
    • 獨立實驗室
    • 公檢室
    • 醫院實驗室
    • 從業者實驗室
    • 審計機構
    • 認證機構

第 5 章市場趨勢

  • 生長促進劑
    • 可能的結果
    • 伴隨診斷
    • 融資
    • 技術環境
    • 目標解決方案
  • 生長抑製劑
    • 診斷的複雜作用
    • 臨床試驗的作用
    • 協議
  • 診斷技術的發展
    • 組合:問題和復雜性
    • 診斷角色的變化
    • 多路復用和 FoundationOne
    • 顛覆趨勢
    • 生物標誌物競賽
    • 未來 5 年展望

第 6 章癌症免疫診斷:近期趨勢

  • 本節的重要性以及如何使用它

第7章主要癌症免疫公司簡介

  • 10x Genomics, Inc.
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc
  • Agilent/Dako
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • BioIVT
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Burning Rock
  • Cancer Genetics
  • Cardiff Oncology
  • Caris Molecular Diagnostics
  • Castle Biosciences, Inc.
  • CellMax Life
  • Cepheid(Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Enzo Biochem
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fabric Genomics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • GeneFirst Ltd.
  • Genetron Holdings
  • GenomOncology
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HalioDx
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Menarini Silicon Biosystems
  • Millipore Sigma
  • Miltenyi Biotec
  • MIODx
  • miR Scientific
  • Molecular MD
  • MyCartis
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • NGeneBio
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Ortho Clinical Diagnostics
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Qiagen
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostics
  • Screencell
  • Sense Biodetection
  • Serametrix
  • Siemens Healthineers
  • Silicon Biosystems
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singulomics
  • SkylineDx
  • Stratos Genomics
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Todos Medical
  • Volition
  • Vortex Biosciences

第8章全球癌症免疫診斷市場

  • 世界市場:按國家/地區概述
  • 全球市場:按檢測類型概述
  • 世界市場:技術概覽
  • 全球市場:客戶概覽

第 9 章全球癌症免疫診斷市場:按用途

  • 檢查點
  • 細胞因子
  • 種系繼承
  • 遺傳性腫瘤
  • 腫瘤微環境
  • 其他

第 10 章全球癌症免疫診斷市場:按技術

  • NGS(下一代序列)
  • 聚合□鏈反應
  • FISH/IHC
  • 化學/IA
  • 其他技術

第 11 章全球癌症免疫診斷市場:按客戶分類

  • 製藥公司
  • 診所
  • 其他客戶

第12章附錄

目錄

OVERVIEW:

Diagnostics, companion diagnostics, is driving the success of Immuno-oncology Therapeutics. An entire new segment of the diagnostics industry is being created. And its not a small segment either. It promises to grow dramatically. Histology, genomics and liquid biopsy are converging. A complicated network of pharmaceutical companies, diagnostic companies and instrumentation suppliers are jockeying for position in a new approach to conquering cancer. The approach seems to be working and showing great promise.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.

The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size in this new expanded and comprehensive report.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Situation Analysis
  • 1.2 Guide for Executives and Marketing Staff
  • 1.3 Guide for Investment Analysts and Management Consultants

2 Introduction and Market Definition

  • 2.1 What are Immuno-Oncology Diagnostics?
  • 2.2 Immuno-oncology - the looming cure
    • 2.2.1 Immuno-oncology Diagnostics Takes a Leading Role
  • 2.3 Market Definition
    • 2.3.1 Market Size
    • 2.3.2 Currency
    • 2.3.3 Years
  • 2.4 Methodology
    • 2.4.1 Authors
    • 2.4.2 Sources
  • 2.5 Perspective: Healthcare and the IVD Industry
    • 2.5.1 Global Healthcare Spending
    • 2.5.2 Spending on Diagnostics
    • 2.5.3 Important Role of Insurance for Diagnostics

3 Immunotherapy - Guide to Immune Technologies

  • 3.1 The Immune System
    • 3.1.1 Innate immune system
      • 3.1.1.1 Surface barriers
      • 3.1.1.2 Inflammation
      • 3.1.1.3 Complement system
      • 3.1.1.4 Cellular barriers
      • 3.1.1.5 Natural killer cells
    • 3.1.2 Adaptive immune system
      • 3.1.2.1 Lymphocytes
      • 3.1.2.2 Killer T cells
      • 3.1.2.3 Helper T cells
      • 3.1.2.4 Gamma delta T cells
      • 3.1.2.5 B lymphocytes and antibodies
    • 3.1.3 Tumor immunology - the immune surveillance system
  • 3.2 Immuno Oncology Diagnostics
    • 3.2.1 Checkpoint Assays
      • 3.2.1.1 Outlook for Checkpoint Assays
    • 3.2.2 Cytokine Assays
      • 3.2.2.1 Outlook for Cytokine Assays
    • 3.2.3 Genomic Germline
      • 3.2.3.1 Outlook for Genomic Germline
    • 3.2.4 Genomic Tumour
      • 3.2.4.1 Outlook for Genomic Tumour
    • 3.2.5 Tumor Microenviroment
      • 3.2.5.1 Outlook for Tumor Microenvironment
    • 3.2.6 Others
      • 3.2.6.1 Outlook for Other Diagnostics

4 Industry Overview

  • 4.1 Players in a Dynamic Market
    • 4.1.1 Academic Research Lab
    • 4.1.2 Diagnostic Test Developer
    • 4.1.3 Genomic Instrumentation Supplier
    • 4.1.4 Cell Separation and Viewing Instrumentation Supplier
    • 4.1.5 Pharmaceutical/Reagent Supplier
    • 4.1.6 Independent Testing Lab
    • 4.1.7 Public National/regional lab
    • 4.1.8 Hospital lab
    • 4.1.9 Physician Lab
    • 4.1.10 Audit Body
    • 4.1.11 Certification Body

5 Market Trends

  • 5.1 Factors Driving Growth
    • 5.1.1 Outcome potential
    • 5.1.2 Companion Diagnostics
    • 5.1.3 Funding
    • 5.1.4 Technology Environment
    • 5.1.5 Target Solutions
  • 5.2 Factors Limiting Growth
    • 5.2.1 Complex Role of Diagnostics
    • 5.2.2 Clinical Trials Role
    • 5.2.3 Protocols
  • 5.3 Diagnostic Technology Development
    • 5.3.1 Combinations - Issues and Complexity
    • 5.3.2 Shifting Role of Diagnostics
    • 5.3.3 Multiplexing and Foundation One
    • 5.3.4 The Disruption Dynamic
    • 5.3.5 The Race for Biomarkers
    • 5.3.6 The Next Five Years

6 Cancer Immuno-Oncology Diagnostics Recent Developments

  • 6.1 Recent Developments - Importance and How to Use This Section
    • 6.1.1 Importance of These Developments
    • 6.1.2 How to Use This Section
  • 6.2 OncoHost Expands Prophet Platform Research
  • 6.3 Protein-Based Liquid Biopsy Panel Assesses TME
  • 6.4 Oncimmune Announces Sixfold Revenue Increase
  • 6.5 Mayo Clinic, Personalis Ink Collaboration
  • 6.6 Lucence Liquid Biopsy Test Tracks Immune Treatment ctDNA
  • 6.7 Qiagen, OncXerna Close Companion Dx Development Deal
  • 6.8 Natera Test to Guide Therapy for Bladder Cancer
  • 6.9 Veracyte Halio Acquisition to Boost Immuno-oncology Activity
  • 6.10 Freenome Eyes New Dx Possibilities
  • 6.11 Oncocyte Data has Potential as Immunotherapy Response
  • 6.12 OncoDNA use HalioDx to Expand into North America
  • 6.13 Adaptive Biotechnologies, Q2 Solutions Agreement for ImmunoSeq
  • 6.14 Qiagen Expands Immuno-Oncology Portfolio
  • 6.15 Immune Profiling System Redirected to Fight COVID-19
  • 6.16 IncellDx Awarded PD-L1 Detection Patent
  • 6.17 FDA Approves CDx for Trastuzumab
  • 6.18 Promega Nabs CE Mark for Microsatellite Instability IVD
  • 6.19 ArcherDx partners with AstraZeneca for Immuno-Oncology
  • 6.20 Germline Results Guides Precision Therapy
  • 6.21 Agilent PD-L1 Assay Gets FDA Approval
  • 6.22 Bayer, OrigiMed Form Companion Diagnostic Development Alliance
  • 6.23 Bio-Me to Develop Microbiome Biomarker Test for Cancer Immunotherapy123
  • 6.24 SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological Signatures
  • 6.25 Biocare Medical Launches 7 Novel IVD Antibodies
  • 6.26 Oncocyte to Acquire Insight Genetics for $12M
  • 6.27 Novigenix and BioLizard to develop NGS Based Diagnostic Algorithm
  • 6.28 Biodesix and Immodulon Collaborate for Pancreatic Cancer Treatment
  • 6.29 Generex to Merge with NuGenerex Immuno-Oncology
  • 6.30 Cellgen Diagnostics and Genomic Testing Cooperative Partner to Develop Companion Diagnostics for Cancer Therapies
  • 6.31 Hematogenix Launches FDA Approved Immuno-oncology Test for Triple-Negative Breast Cancer
  • 6.32 Icon Acquires MolecularMD

7 Profiles of Key Immuno-oncology Companies

  • 7.1 10x Genomics, Inc.
  • 7.2 Abbott Diagnostics
  • 7.3 AccuraGen Inc.
  • 7.4 Adaptive Biotechnologies
  • 7.5 Aethlon Medical
  • 7.6 Agena Bioscience, Inc
  • 7.7 Agilent/Dako
  • 7.8 Anchor Dx
  • 7.9 ANGLE plc
  • 7.10 ApoCell, Inc.
  • 7.11 ARUP Laboratories
  • 7.12 Asuragen
  • 7.13 AVIVA Biosciences
  • 7.14 Baylor Miraca Genetics Laboratories
  • 7.15 Beckman Coulter Diagnostics
  • 7.16 BGI Genomics Co. Ltd
  • 7.17 Bioarray Genetics
  • 7.18 Biocartis
  • 7.19 Biocept, Inc.
  • 7.20 Biodesix Inc.
  • 7.21 BioFluidica
  • 7.22 BioGenex
  • 7.23 BioIVT
  • 7.24 Biolidics Ltd
  • 7.25 bioMérieux Diagnostics
  • 7.26 Bioneer Corporation
  • 7.27 Bio-Rad Laboratories, Inc.
  • 7.28 Bio-Reference Laboratories
  • 7.29 Bio-Techne
  • 7.30 Bioview
  • 7.31 Bolidics
  • 7.32 Boreal Genomics
  • 7.33 Bristol-Myers Squibb
  • 7.34 Burning Rock
  • 7.35 Cancer Genetics
  • 7.36 Cardiff Oncology
  • 7.37 Caris Molecular Diagnostics
  • 7.38 Castle Biosciences, Inc.
  • 7.39 CellMax Life
  • 7.40 Cepheid (Danaher)
  • 7.41 Charles River Laboratories
  • 7.42 Chronix Biomedical
  • 7.43 Circulogene
  • 7.44 Clinical Genomics
  • 7.45 Cynvenio
  • 7.46 Cytolumina Technologies Corp.
  • 7.47 CytoTrack
  • 7.48 Datar Cancer Genetics Limited
  • 7.49 Diagnologix LLC
  • 7.50 Diasorin S.p.A.
  • 7.51 Enzo Biochem
  • 7.52 Epic Sciences
  • 7.53 Epigenomics AG
  • 7.54 Eurofins Scientific
  • 7.55 Exosome Diagnostics
  • 7.56 Exosome Sciences
  • 7.57 Fabric Genomics
  • 7.58 Fluidigm Corp
  • 7.59 Fluxion Biosciences
  • 7.60 Foundation Medicine
  • 7.61 Freenome
  • 7.62 FUJIFILM Wako Diagnostics
  • 7.63 GeneFirst Ltd.
  • 7.64 Genetron Holdings
  • 7.65 GenomOncology
  • 7.66 GILUPI Nanomedizin
  • 7.67 Grail, Inc.
  • 7.68 Guardant Health
  • 7.69 HalioDx
  • 7.70 HansaBiomed
  • 7.71 HeiScreen
  • 7.72 Helomics
  • 7.73 Horizon Discovery
  • 7.74 HTG Molecular Diagnostics
  • 7.75 iCellate
  • 7.76 Illumina
  • 7.77 Incell Dx
  • 7.78 Inivata
  • 7.79 Integrated Diagnostics
  • 7.80 Invitae Corporation
  • 7.81 Invivogen
  • 7.82 Invivoscribe
  • 7.83 Janssen Diagnostics
  • 7.84 MDNA Life SCIENCES, Inc.
  • 7.85 MDx Health
  • 7.86 Menarini Silicon Biosystems
  • 7.87 Millipore Sigma
  • 7.88 Miltenyi Biotec
  • 7.89 MIODx
  • 7.90 miR Scientific
  • 7.91 Molecular MD
  • 7.92 MyCartis
  • 7.93 Myriad Genetics/Myriad RBM
  • 7.94 NantHealth, Inc.
  • 7.95 Natera
  • 7.96 NeoGenomics
  • 7.97 New Oncology
  • 7.98 NGeneBio
  • 7.99 Novogene Bioinformatics Technology Co., Ltd.
  • 7.100 Oncocyte
  • 7.101 OncoDNA
  • 7.102 Ortho Clinical Diagnostics
  • 7.103 Oxford Nanopore Technologies
  • 7.104 Panagene
  • 7.105 Perkin Elmer
  • 7.106 Personal Genome Diagnostics
  • 7.107 Personalis
  • 7.108 Precipio
  • 7.109 PrecisionMed
  • 7.110 Promega
  • 7.111 Qiagen
  • 7.112 Rarecells SAS
  • 7.113 RareCyte
  • 7.114 Roche Molecular Diagnostics
  • 7.115 Screencell
  • 7.116 Sense Biodetection
  • 7.117 Serametrix
  • 7.118 Siemens Healthineers
  • 7.119 Silicon Biosystems
  • 7.120 simfo GmbH
  • 7.121 Singlera Genomics Inc.
  • 7.122 Singulomics
  • 7.123 SkylineDx
  • 7.124 Stratos Genomics
  • 7.125 Sysmex Inostics
  • 7.126 Tempus Labs, Inc.
  • 7.127 Thermo Fisher Scientific Inc.
  • 7.128 Thrive Earlier Detection
  • 7.129 Todos Medical
  • 7.130 Volition
  • 7.131 Vortex Biosciences

8 The Global Market for Immuno-Oncology Diagnostics

  • 8.1 Global Market Overview by Country
    • 8.1.1 Table - Global Market by Country
    • 8.1.2 Chart - Global Market by Country
  • 8.2 Global Market by Assay Type - Overview
    • 8.2.1 Table - Global Market by Assay Type
    • 8.2.2 Chart - Global Market by Assay Type - Base/Final Year Comparison
    • 8.2.3 Chart - Global Market by Assay Type - Base Year
    • 8.2.4 Chart - Global Market by Assay Type - End Year
    • 8.2.5 Chart - Global Market by Assay Type - Share by Year
    • 8.2.6 Chart - Global Market by Assay Type - Segments Growth
  • 8.3 Global Market by Technology - Overview
    • 8.3.1 Table - Global Market by Technology
    • 8.3.2 Chart - Global Market by Technology - Base/Final Year Comparison
    • 8.3.3 Chart - Global Market by Technology - Base Year
    • 8.3.4 Chart - Global Market by Technology - End Year
    • 8.3.5 Chart - Global Market by Technology - Share by Year
    • 8.3.6 Chart - Global Market by Technology - Segments Growth
  • 8.4 Global Market by Customer - Overview
    • 8.4.1 Table - Global Market by Customer
    • 8.4.2 Chart - Global Market by Customer - Base/Final Year Comparison
    • 8.4.3 Chart - Global Market by Customer - Base Year
    • 8.4.4 Chart - Global Market by Customer - End Year
    • 8.4.5 Chart - Global Market by Customer - Share by Year
    • 8.4.6 Chart - Global Market by Customer - Segments Growth

9 Global Immuno-Oncology Diagnostic Markets - By Application

  • 9.1 Checkpoint
    • 9.1.1 Table Checkpoint - by Country
    • 9.1.2 Chart - Checkpoint Growth
  • 9.2 Cytokine
    • 9.2.1 Table Cytokine - by Country
    • 9.2.2 Chart - Cytokine Growth
  • 9.3 Germline Genetic
    • 9.3.1 Table Germline Genetic - by Country
    • 9.3.2 Chart - Germline Genetic Growth
  • 9.4 Genetic Tumor
    • 9.4.1 Table Genetic Tumor - by Country
    • 9.4.2 Chart - Genetic Tumor Growth
  • 9.5 Tumor Microenvironment
    • 9.5.1 Table Tumor Microenvironment - by Country
    • 9.5.2 Chart - Tumor Microenvironment Growth
  • 9.6 Other
    • 9.6.1 Table Other - by Country
    • 9.6.2 Chart - Other Growth

10 Global Immuno-Oncology Diagnostic Markets - By Technology

  • 10.1 NGS
    • 10.1.1 Table NGS - by Country
    • 10.1.2 Chart - NGS Growth
  • 10.2 PCR
    • 10.2.1 Table PCR - by Country
    • 10.2.2 Chart - PCR Growth
  • 10.3 Fish/IHC
    • 10.3.1 Table Fish/IHC - by Country
    • 10.3.2 Chart - Fish/IHC Growth
  • 10.4 Chem/IA
    • 10.4.1 Table Chem/IA - by Country
    • 10.4.2 Chart - Chem/IA Growth
  • 10.5 Other Technology
    • 10.5.1 Table Other Technology - by Country
    • 10.5.2 Chart - Other Technology Growth

11 Global Immuno-Oncology Diagnostic Markets - By Customer

  • 11.1 Pharma
    • 11.1.1 Table Pharma - by Country
    • 11.1.2 Chart - Pharma Growth
  • 11.2 Clinic
    • 11.2.1 Table Clinic - by Country
    • 11.2.2 Chart - Clinic Growth
  • 11.3 Other Customer Genetic
    • 11.3.1 Table Other Customer - by Country
    • 11.3.2 Chart - Other Customer Growth

12 Appendices

  • 12.1 FDA Cancer Drug Approvals by Year
  • 12.2 Clinical Trials Started 2010 to 2016
  • 12.3 Prevalence of Cancer Treatments
  • 12.4 United States Medicare System: 2022 Clinical Laboratory Fees Schedule

Table of Tables

  • Table 1 List of Cancers by Mortality
  • Table 2 Overview of Innate and Adaptive Immunity
  • Table 3 FDA Approved Monoclonal Antibodies in Cancer treatment
  • Table 4 FDA Approved Companion diagnostics in Cancer treatment
  • Table 5 Market Players by Type
  • Table 6 Five Factors Driving Growth
  • Table 7 Three Factors Limiting Growth
  • Table 8 - Global Market by Region
  • Table 9 Global Market by Assay Type
  • Table 10 Global Market by Technology
  • Table 11 Global Market by Customer
  • Table 12 Checkpoint by Country
  • Table 13 Cytokine by Country
  • Table 14 Germline Genetic by Country
  • Table 15 Genetic Tumor by Country
  • Table 16 Tumor Microenvironment by Country
  • Table 17 Other by Country
  • Table 18 NGS by Country
  • Table 19 PCR by Country
  • Table 20 Fish/IHC by Country
  • Table 21 Chem/IA by Country
  • Table 22 Other Technology by Country
  • Table 23 Pharma by Country
  • Table 24 Clinic by Country
  • Table 25 Other Customer by Country
  • Table 26 2022 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Cancer Death Rates - USA, CDC
  • Figure 2 World Health Care Spending
  • Figure 3 The Lab Test Pie
  • Figure 4 Helper T Cell Roles
  • Figure 5 Antibody Diagram
  • Figure 6 Macrophages attack a Cancer Cell
  • Figure 7 The Tumour Micro Environment
  • Figure 8 Comparing IO Diagnostic and Traditional Testing
  • Figure 9 Growth rates of IO DiagnosticTechnologies
  • Figure 10 Global Market Density Chart
  • Figure 11 Global Market by Assay Type - Base vs. Final
  • Figure 12 Global Market by Assay Type Base Year
  • Figure 13 Global Market by Assay Type End Year
  • Figure 14 Assay Type Share by Year
  • Figure 15 Assay Type Segments Growth
  • Figure 16 Global Market by Technology - Base vs. Final
  • Figure 17 Global Market by Technology Base Year
  • Figure 18 Global Market by Technology End Year
  • Figure 19 Technology Share by Year
  • Figure 20 Technology Segments Growth
  • Figure 21 Global Market by Customer - Base vs. Final
  • Figure 22 Global Market by Customer Base Year
  • Figure 23 Global Market by Customer End Year
  • Figure 24 Customer Share by Year
  • Figure 25 Customer Segments Growth
  • Figure 26 Checkpoint Growth
  • Figure 27 Cytokine Growth
  • Figure 28 Germline Genetic Growth
  • Figure 29 Genetic Tumor Growth
  • Figure 30 Tumor Microenvironment Growth
  • Figure 31 Other Growth
  • Figure 32 NGS Growth
  • Figure 33 PCR Growth
  • Figure 34 Fish/IHC Growth
  • Figure 35 Chem/IA Growth
  • Figure 36 Other Technology Growth
  • Figure 37 Pharma Growth
  • Figure 38 Clinic Growth
  • Figure 39 Other Customer Growth
  • Figure 40 FDA Cancer Drug Approvals by Year
  • Figure 41 Clinical Trials for Immunotherapy by Year
  • Figure 42 Pie Chart of Prevalence of Cancer Treatments